Imaging-Based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy

Last Updated: Tuesday, February 22, 2022

Investigators found that thoracic imaging findings, including pleural effusions and atelectasis, correlated with cytokine release syndrome grade following chimeric antigen receptor (CAR) T-cell infusion. CAR T-cell therapy yielded high response rates.

Radiology

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Blood

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

Mayo Clinic Proceedings. Innovations, Quality, & Outcomes

Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Blood Advances

CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations

CAR T-Cell Therapy Resource Center

Imaging-Based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Blood

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

Mayo Clinic Proceedings. Innovations, Quality, & Outcomes

Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Blood Advances

CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets